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 Resumo 
Introdução – A prevalência de doentes HIV está a aumentar em todo o mundo, uma vez 
que a sua esperança media de vida aumentou com a introdução dos agentes 
antirretrovirais. Estes doentes desenvolvem muitas vezes doenças inflamatórias que são 
frequentemente refratárias ao tratamento.  
A Psoríase é uma doença inflamatória sistémica, associada tanto a sofrimento físico 
como psicológico, e pode ser a primeira manifestação da infeção por HIV.  
Em doentes HIV, esta doença tem tendência a ser mais grave, ter apresentações atípicas 
e os tratamentos prescritos têm menores taxas de eficácia. Embora a Psoríase leve a 
moderada seja tratável, a doença grave é de tratamento mais difícil, e os efeitos 
secundários dos fármacos imunossupressores, como as infeções oportunistas, são a 
maior preocupação. 
Objetivos – Proponho-me a realizar uma pesquisa de artigos científicos em bases de 
dados disponíveis (Pubmed, Medscape, revistas científicas, entre outras,) e estruturar a 
informação selecionada numa dissertação concisa sobre o tema.  
Desenvolvimento – Psoríase foi observada em todos os estádios da infeção por HIV, 
incluindo como uma manifestação da síndrome inflamatória de reconstituição imune.  
Muitos dos tratamentos sistémicos da psoríase são imunossupressores e podem ter 
complicações severas em contexto HIV.  
Terapêuticas tópicas são utilizadas para a doença leve ou moderada, ou na moderada a 
grave como adjuvante. Deste modo, podem ser usadas isoladamente ou associadas com 
fototerapia/agentes sistémicos.  
Nos doentes HIV, os antirretrovirais devem ser considerados como terapia de primeira 
linha para psoríase moderada a grave, e em alguns doentes podem ser utilizados em 
monoterapia.  
Agentes sistémicos orais são utilizados como segunda linha. Os retinóides orais são 
comumente utlizados para este efeito e representam uma alternativa não 
imunossupressora.   
Em doentes refratários ao tratamento, o uso de imunossupressores como o 
Metotrexato, Ciclosporina e Hidroxiureia são uma opção, embora o risco de surgimento 
de infeções oportunistas seja uma preocupação.  
 Por outro lado, os inibidores do TNF-α são geralmente utilizados juntamente com 
fototerapia ou quando as terapias sistémicas convencionais falham, são contraindicadas 
ou não toleradas. 
 
Conclusões – O tratamento da Psoríase em doentes HIV é um desafio, e deve ser 
baseado na gravidade da doença, e no risco-benefício de cada tratamento. Os 
tratamentos de primeira linha incluem terapia tópica, fototerapia, antirretrovirais, e em 
segunda linha retinoides orais. Na doença refratária tratamento cuidadoso com 
imunossupressores deve ser considerado. Agentes biológicos podem também ser uma 
boa opção para estes casos. No entanto, independentemente da terapia utilizada, estes 
doentes devem ser seguidos atentamente, devido ao potencial risco de efeitos adversos, 
com monitorização regular das contagens CD4 e viremia. 
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Abstract 
 
HIV prevalence is increasing worldwide as people on antiretroviral therapy are living 
longer. These patients are often susceptible to debilitating inflammatory disorders that 
are frequently refractory to standard treatment. Psoriasis is a systemic inflammatory 
disorder, associated with both physical and psychological burden, and can be the 
presenting feature of HIV infection. In this population, psoriasis tends to be more severe, 
to have atypical presentations and higher failure rates with the usual prescribed 
treatments.  
Management of moderate and severe HIV-associated psoriasis is challenging. 
Systemic conventional and biologic agents may be considered, but patients should be 
carefully followed up for potential adverse events, like opportunist infections, and 
regular monitoring of CD4 counts and HIV viral loads.  
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Introduction 
HIV prevalence is increasing worldwide as patients on antiretroviral therapy 
(ART) are living longer. In 2012 an estimated 35.3 million people were living with HIV. 1  
Dermatological disorders, such as psoriasis, can be the presenting feature of HIV 
infection. Moreover, in the HIV-infected population, psoriasis tends to be more severe 
(with severe disease correlating with higher immunosuppression)2,3, to have atypical 
presentations and higher failure rates with the usual prescribed treatments.4 Although 
mild psoriasis is usually manageable, moderate to severe disease is more difficult to 
treat, and side effects from immunosuppressive drugs, such as, opportunistic infections, 
are the main concern. 
  This review discusses the pathogenesis, clinical features and management of 
HIV-associated psoriasis.   
 
Psoriasis  
Psoriasis is a systemic inflammatory disorder5, associated with both physical and 
psychological burden.6 
Five types of psoriasis have been described: plaque-type psoriasis, guttate 
psoriasis, inverse psoriasis, pustular psoriasis (either localized or generalized pustular 
psoriasis), and erythrodermic psoriasis.5 Concomitant psoriatic arthritis occurs in up to 
30-40% of patients.7 Psoriasis shows characteristic histopathological changes including 
epidermal acanthosis, hyperkeratosis, and parakeratosis, as well as premature 
desquamation of the stratum corneum. In the dermis, dilated and contorted blood 
vessels reach into the tips of the dermal papillae. There is also an inflammatory infiltrate 
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containing T cells, and an increased number of macrophages, mast cells and neutrophils. 
These cells accumulate within the epidermis forming Munro’s microabscesses.5 
Involvement of the immune system in psoriasis is widely accepted.8,9 Specific 
subpopulations of dendritic cells (DCs), both myeloid (mDCs) and plasmacytoid (pDCs) 
could be recognized as central in the early pathogenetic steps of psoriasis.10 Indeed, 
their activation induced by chemerin, LL37-DNA or LL37-RNA complexes, could trigger 
the psoriasis inflammatory cascade through the production of several proinflammatory 
mediators.11–13 pDCs mainly contribute producing IFN-α, while mDCs secrete IL-20, 
which promotes keratinocyte proliferation, nitric oxide, TNF-α, IL-12 (Th1-differentiating 
cytokine) and IL-23, which sustains differentiation, activation and expansion of IL-17-
producing CD4+ T cells.14–16  Additionally, IL-23 stimulates other IL-17-producing T cells 
including CD8+ T cells, named T cytotoxic (Tc)-17, α/β and γ/δ T cells.17–21 Furthermore, 
various immune cells, namely neutrophils, mast cells and innate lymphoid cells, 
contribute to the elevated IL-17 expression levels detected in lesioned psoriatic skin. 22–
25 Although less pathogenically relevant compared with the IL-23/Th17 pathway, 
increasing evidence also suggested an involvement of multiple T-cell subsets (i.e., Th1, 
Th9, Th21 and Th22, Tc1) in psoriasis pathogenesis. 17,26,27 Tissue cells, especially 
keratinocytes, but also fibroblasts and endothelial cells are the key responding cells to 
these inflammatory pathways. T-cell cytokines stimulate proliferation and activation of 
keratinocytes, inducing acanthosis and, in turn, production of several proinflammatory 
mediators including IL-1β, IL-6, TNF-α, chemokines and anti-microbial peptides, which 
sustain and amplify immune cell recruitment, retain and activation within lesional 
skin.17,28 
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Psoriasis is also associated with several important comorbidities, including 
Crohn’s disease, cancer, depression, non-alcoholic fatty liver disease, metabolic 
syndrome (or its components), and cardiovascular disease (CVD).29,30 These associations 
might be due to similarities in the genetic basis and due to systemic inflammation mainly 
seen in severe psoriasis.31  
 
HIV 
There are two types of HIV: HIV-1 and HIV-2. HIV-1 has marked genetic diversity 
as a consequence of the error-prone function of reverse transcriptase, resulting in a high 
mutation rate. HIV-2 is largely confined to West Africa, less transmissible and although 
it causes a similar illness, immunodeficiency progresses more slowly.32 
The hallmark of HIV infection is the progressive depletion of CD4 T cells due to 
reduced production and increased destruction. CD4 T cells are eliminated by direct 
infection, and bystander effects of syncytia formation, immune activation, proliferation, 
and senescence. In early infection, a reduction in circulating CD4 T cells is followed by 
recovery to near normal concentrations, which slowly decreases by about 50-100 
cells/μL per year.33 HIV infection is also characterized by a marked increase in immune 
activation, which includes both the adaptive and innate immune systems.34 The drivers 
for immune activation include the direct effects of HIV as a ligand for the Toll-like 
receptor (TLR7 and TLR 8) expressed on plasmacytoid dendritic cells, leading to 
production of interferon-α;35 microbial translocation, with lipopolysaccharide as a 
potent activator of TLR4 leading to the production of proinflammatory cytokines such 
as IL-6 and TNF-α; 36 co-infection with viruses that induce profound expansion of 
activated T cells; 37and a reduced ratio of T-helper-17 and regulatory T cells, especially 
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in the gastrointestinal tract. 38 Evidence of residual inflammation or increased immune 
activation exists, even in patients with HIV with adequate CD4 T cell restoration on ART. 
Aging with HIV is often linked to non-infectious comorbidities, including CVD, 
hypertension, type 2 diabetes mellitus, chronic kidney disease, 
osteopenia/osteoporosis, and non-AIDS cancers. These heterogeneous comorbidities 
share age and presumably HIV-infection as independent risk factors, and tend to 
aggregate into complex multi-morbidity patterns. 39,40 The pathophysiology of HIV-
associated CVD includes an intricate interplay of inflammation, direct effects of HIV 
proteins, immune dysfunction, drug effects, malnutrition, and other factors. 
Inflammation and dyslipidemia drive the pathophysiology of coronary artery disease 
(CAD) in patients infected with HIV. In particular, persistent HIV viral replication, 41 
microbial translocation,42 and coinfections (eg, cytomegalovirus) contribute to a 
proinflammatory milieu that accelerates atherosclerosis. 43 The development of ART 
transformed HIV from an illness with a fatal outcome to a chronic manageable disease. 
Standard regimens combine two nucleoside reverse transcriptase inhibitors with a non-
nucleoside reverse transcriptase inhibitor, protease inhibitor, or integrase inhibitor. 
After initiation of ART, the plasma viral load decreases to concentrations below the 
lower limit of detection of available commercial assays in most people within 3 months. 
By contrast, the recovery of CD4 T cells in treated individuals is variable. 44 However, 
prolonged ART use predisposes to dyslipidemia, hyperglycemia, and lipodystrophy, 
among other side effects.45 Protease inhibitors (PIs), particularly older generation PIs, 
are commonly implicated in ART-associated dyslipidemia, and are associated with 
greater risk of acute myocardial infarction.46,47 They are postulated to increase CVD risk 
by inducing dyslipidemia and reactive oxygen species production, with resultant 
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mitochondrial dysfunction, fatty infiltration in liver and muscle, and insulin resistance. 
48 In high income countries, these effects, compounded with the cardiac effects of aging 
and inflammation, contribute to an increased risk of numerous CVDs. 45 On the other 
hand, in regions where ART initiation is often delayed and access is limited, the 
predominant manifestations are still related to opportunistic, infection-related 
myopericardial disease. 49  
 
Psoriasis and HIV 
Psoriasis has been observed in all stages of HIV infection and in some patients 
may be the initial presentation of the infection. In patients with pre-existing psoriasis, 
exacerbation of the disease is common when HIV infection occurs. 50  
Exacerbations of psoriasis by staphylococcal and streptococcal infection are also 
more common in patients with HIV than in those without, and heavy colonization 
prolongs the disease course. 51 Interestingly, it has been shown that genetic variants that 
contribute to anti-viral immunity may predispose to the development of psoriasis, as 
psoriasis patients are significantly more likely to have gene variants protective against 
HIV-1 disease. It was also found that the compound genotype KIR3DS1 plus HLA-B Bw4-
80I, which respectively encode a natural killer cell activating receptor and its putative 
ligand, significantly increase psoriasis susceptibility and is associated with delay of 
progression to AIDS.52  
 In HIV context, T-cell imbalance, may be responsible in part for the development 
of worsening of psoriasis, due to the depletion of CD4 suppressor T cells, resulting in 
unchecked proinflammatory pathways. 53 Furthermore, HIV RNA transcripts have been 
identified in the skin of patients with HIV-associated psoriasis and within CD4 Factor 
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XIIIa+ dermal dendritic cells, which suggests a direct role of HIV and is compatible with 
worsening disease with the higher viral loads associated with progressive 
immunodeficiency. 54 HIV might also directly trigger psoriasis as a costimulatory factor 
through antigenic presentation or as a source of superantigens . 53 In HIV-associated 
psoriasis HIV Negative Regulatory Factor (nef) protein has superantigen properties. 55 
Moreover, infections by virus and bacteria, which are common in HIV, might contribute 
to epitope spreading. 54 
Psoriasis has also been reported as a manifestation of HIV-related immune 
reconstitution inflammatory syndrome (IRIS). IRIS is an exacerbation or emergence of a 
previously unknown disease resulting from rapid restoration of pathogen-specific 
immune responses to pre-existing antigens combined with immune dysregulation, 
which happens shortly after initiation of ART.   IRIS happens more commonly when ART 
is started in patients with low CD4 counts or soon after starting treatment for 
opportunistic infections. Strategies to reduce IRIS include initiation of ART at high CD4 
counts, delayed initiation in patients with an infection, and screening for and prevention 
of opportunistic infections. 56 There is emerging evidence that one of the 
immunopathogenic mechanisms of IRIS involves the rapid and dysregulated shift from 
the T helper 2 predominant state of advanced HIV infection to the Th1 and Th17 
dominant state of immune recovery. 57  
As discussed above, HIV-infection and psoriasis are conditions in which CVD are 
an important group of comorbid diseases. As such, screening, monitoring and treatment 
of cardiometabolic risk factors and CVD is important in psoriasis patients infected with 
HIV, since these patients are more prone to develop such diseases. 
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Clinical Features 
Incidence rates of Psoriasis in HIV patients are similar to those reported in the 
general population.4 However, misleading and unusual clinical presentations, severe 
disease, and frequent exacerbations are characteristic. 51 Although all clinical subtypes 
of psoriasis may occur in patients with HIV-associated psoriasis, guttate, inverse, and 
erythrodermic occur with higher frequencies. 2,3,58 Often, more than one morphological 
type of psoriasis may coexist in a single patient, which is a distinguishing hallmark 
feature of HIV-associated psoriasis. 3 
As in non-HIV patients, plaque-type psoriasis is the most common form of the 
disease, and accounts for about 90% of cases. However, in this specific population there 
is a predilection for scalp lesions, palmoplantar and flexural involvement, as well as a 
trend towards severe immunodeficiency with CD4 counts below 200 cells/mm3. 4,59 On 
the other hand, different clinical variants can develop over the course of the disease. 
Often there is no family history of psoriasis. 54  
Sebopsoriasis is more common in patients with HIV. The clinical features 
represent an overlap between seborrheic dermatitis and psoriasis. Greasy scales with 
exudative crusts affect seborrheic areas on the scalp, retroauricular, perinasal, and 
flexural areas, and upper trunk.60 Sebopsoriasis can be triggered by yeasts, and the 
effectiveness of systemic or topical antifungals is helpful in distinguishing this variant 
from classic psoriasis. 61 
Rupioid psoriasis is one of the rarer variants of psoriasis, and has also been 
reported as a manifestation of HIV-associated psoriasis. This variant is characterized by 
limpet-like, cone-shaped, hyperkeratotic nodules and plaques covered with an 
exudative crust typically presenting on the limbs. 54  
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Psoriatic arthritis is much more destructive and refractory to conventional 
treatments in the HIV population, and its prevalence is also greatly increased compared 
with its immunocompetent counterpart. 62,63 Reactive arthritis prevalence is also higher 
in patients with HIV. This disease is a seronegative spondyloarthropathy characterized 
by a triad of arthritis, urethritis, and conjunctivitis.64 A reactive arthritis-like psoriasis 
syndrome is a recognized presentation in HIV-associated psoriasis. 51 The typical 
cutaneous presentation of this variant, seen in more than half of patients, is 
keratoderma blennorrhagica with palmoplantar psoriasiform plaques. The histology is 
identical to that of pustular psoriasis.54  
 
Diagnosis and differential diagnosis 
Cutaneous diseases are common manifestations of HIV infection and AIDS, and 
may be indicative of the degree of immune dysfunction. Psoriasis can be the presenting 
feature of HIV infection and can provide a clinical clue as to the state of the patient’s 
immune system.65 The patient’s history should include details of family members with 
the disease, and potential trigger factors, such as present infections or new 
medications.66 As in non-HIV patients, psoraisis diagnosis is usually made on clinical 
findings and skin biopsy is rarely needed. The Psoriasis Area and Severity Index (PASI) 
score is usually used to quantify disease severity.67 Joint involvement should also be 
inquired, especially in HIV patients. In the presence of the extremely rare rupioid 
psoriasis, physicians should suspect immunosuppression, such as HIV/AIDS, or other 
immune dysregulaton.65 
The most common differential diagnosis of psoriasis includes tinea infection, 
seborrheic dermatitis and eczema of several causes. less common differential diagnosis 
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includes lichen planus, pityriasis rubra pilaris (PRP), pityriasis rosea and cutaneous 
lymphoma. 59 While PRP is a rare disease that can be associated with HIV infection (type 
VI) and is characterized by follicular keratotic papules or plaques that may coalesce to 
form erythematous or salmon-colored plaques that can develop scales68, cutaneous 
non-Hodgkin's lymphomas are rare in patients with HIV-1 infection and almost all of the 
cases reported are of T-cell lineage with histopathological features of mycosis fungoides 
or Sezary syndrome. 69 
Papulosquamous secondary syphilis might clinically and histologically resemble 
psoriasis and can be distinguished by other clinical clues of syphilis, such as so-called 
moth-eaten alopecia, condylomata lata in the flexures and perineum, and positive 
syphilis serology. A high index of suspicion is needed since false negative syphilis 
serology might initially be encountered due to the so-called prozone phenomenon 
associated with high treponemal loads with HIV. 54 
Annular psoriasis might be confused with ringworm; skin scrapings for fungal 
microscopy and culture help distinguish the latter. Microscopy can also be helpful to 
exclude crusted scabies, to which patients with HIV are prone, and is highly contagious 
if undiagnosed. The clinical presentation can mimic psoriasis since the lesions are often 
non-pruritic and present as scaly plaques on the skin, scalp and nails. 70 
In cases of nail psoriasis, care must be taken to exclude onychomycosis, since the 
clinical features can be similar and is common in HIV patients. 54 
Some patients with erythrodermic psoriasis have large scales resembling either 
lamellar ichthyosis or a chronic erythrodermic drug eruption. Patients infected with HIV 
are particularly prone to the latter; hence, a careful history and a high index of suspicion 
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are needed. These patients can develop generalized skin failure associated with higher 
mortality. 54  
Treatment 
The treatment of psoriasis in HIV-infected patients poses a distinct therapeutic 
challenge as HIV-associated psoriasis is a T-cell mediated disease in the setting of T-cell 
depletion. Many of the systemic treatments for psoriasis are immunosuppressive and 
potentially can lead to severe complications in the setting of HIV infection. 3 
Topical therapies may be used alone or in combination with other treatment 
modalities, including phototherapy and systemic agents. These therapies are 
appropriate for treatment of mild to moderate disease or as an adjunctive treatment for 
moderate to severe disease. 71  
Glucocorticosteroids, vitamin D derivatives, or combinations of both are usually 
sufficient to manage mild disease. Topical calcineurin inhibitors are used for difficult to 
treat sites, such as the intertriginous areas or the face. 59 Side effects from topical 
therapies in HIV patients are comparable with the non-HIV-infected population, and 
similar caution should be exercised when using these agents. 71 
Phototherapy (narrow-band UVB and PUVA) and/or systemic therapy is needed 
for patients with moderate to severe disease. Both UVB and PUVA have been used in 
the treatment of HIV-associated psoriasis. As in the non-HIV infected population, 
phototherapy is clinically effective and provides substantial relief in patients with 
debilitating disease. 71 The carcinogenic potential of PUVA limits its long term use. 59 A 
potential problem associated with the use of UV light is photosensitivity. Patients with 
HIV are prone to photosensitivity either directly due to HIV or ART. 72 Care must be taken 
when selecting patients since there is a raised incidence of non-melanoma skin cancer 
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and melanoma in patients receiving more than 250 treatments of PUVA 73,74but overall 
UVB is thought to be safe. 70  
In HIV patients, ART should also be considered as a first-line therapy for 
moderate to severe psoriasis, and in some patients can be used as monotherapy. 71 
Improvement of HIV associated psoriasis after the initiation of ART has been reported in 
several case reports. 75,76,77 
As second-line therapy for moderate to severe psoriasis, systemic oral agents are 
recommended. Oral retinoids are the most commonly used and represent an effective, 
non-immunosupressive alternative. Retinoids are successful as monotherapy or as part 
of combination regimens, mainly with UV therapy. An additional effect is that lower 
cumulative doses of UV can be used.  Dosing for HIV patients is similar to the non-HIV, 
although higher doses may be required to achieve optimal results. 78,79 
In refractory patients immunosuppressants such as methotrexate (MTX), 
cyclosporine (CSA) and hydroxyurea are an option; however, in the HIV-infected 
population opportunistic infections are a concern.  
Although MTX is a key treatment in classic psoriasis and has been used for HIV-
associated psoriasis, it is hepatotoxic and can cause leucopenia and opportunistic 
infections, hence it should be used with caution. 54 
Cyclosporine exerts its immunomodulatory effect by inhibiting the activation of 
CD4 T cells via calcineurin inhibition. In published cases of treatment of HIV-associated 
psoriasis with CSA, patients experienced rapid clearing of psoriasis without the 
development of opportunistic infections or worsening of immunosuppression. 80,81On 
the other hand, careful monitoring for nephrotoxicity and hypertension is needed. 
Cyclosporine is recommended for short intermittent courses of up to 12 weeks. It can 
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also be used when rapid remission is needed in potentially lethal psoriasis variants such 
as erythroderma or generalized pustular psoriasis. 54  
Hydroxyurea is a systemic immunosuppressive drug. In addition to its anti-
psoriatic effects, it has also been shown to have antiviral effects. This dual effect makes 
it a drug to consider when treating HIV-associated psoriasis. There are multiple reports 
that discuss the safety and efficacy of hydroxyurea in psoriasis and HIV separately. A 
2011 review suggests that hydroxyurea is generally safe and effective. The main risk 
involves the hematologic adverse events (anemia, leukopenia, thrombocytopenia, and 
macrocytosis) which appear to be dose-dependent. Despite this fact, hydroxyurea may 
be considered as a viable option for patients with generalized psoriasis inadequately 
responsive to other safer options, whether the patient is HIV-positive or not. 82 
In the past decade, several biologic agents have been developed and approved 
for the treatment of psoriasis and psoriatic arthritis. TNF-α inhibitors include etanercept, 
adalimumab, and infliximab that are approved for the treatment of psoriasis and 
psoriatic arthritis, and golimumab that has been approved for psoriatic arthritis. 
Ustekinumab is a p40-IL12/23 inhibitor and is approved for both indications while 
secukinumab and ixekizumab are IL-17A inhibitors and have been approved for the 
treatment of psoriasis (secukinumab and ixekizumab) and psoriatic arthritis 
(secukinumab). Biologics agents are used for long-term treatment because there is no 
evidence of cumulative toxicity or drug–drug interactions. Furthermore, these agents 
have a good safety profile with only a small increase in opportunistic infections. TNF-α 
inhibitors are generally used after phototherapy and when conventional systemic 
therapies have either failed, were not tolerated, or were contraindicated. This second-
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line use is in part due to the high direct costs for drugs, which are in the order of ten-
times higher than for conventional systemic drugs. 59 
The American Academy of Dermatology reviewed 27 published cases of patients with 
HIV treated with TNF-α inhibitors. Although their review is limited because no 
randomized controlled trials have been performed with this population, it is proposed 
that reliable seropositive patients, who are adherent to medication regimens and 
frequent monitoring and have failed other treatment modalities, should be considered 
for treatment with TNF-α inhibitors, as anti-TNF-α agents have been used effectively in 
patients with HIV-associated psoriasis and HIV-associated psoriatic arthritis 
unresponsive to a combination methotrexate and ciclosporin. 83, 84, 85 TNF-α is a pivotal 
cytokine in the pathogenesis of granulomatous inflammation, stimulates HIV 
transcription in vitro86 and is thought to be involved in the pathogenesis of aphthous 
ulcers, cachexia, dementia, fatigue and fever in HIV. A concern about the use of this 
therapy is the predisposition to other infections. If TNF-α inhibitors are to be used, other 
comorbidities that are often noted in HIV, such as tuberculosis, hepatitis B, and other 
opportunistic infections, need to be ruled out. Hepatitis C infection, however, is not seen 
as a contraindication to the use of TNF-α inhibitors because they have been used safely 
and effectively in patients with hepatitis C infection.87 The same applies in non-HIV 
population. 54 Regarding ustekinumab there are reports of its use in refractory HIV-
associated psoriasis, which has been described as safe and efficient, and without side 
effects or decrease in CD4 counts,88,89 while the use and safety of secukinumab and 
ixekizumab have yet to be established in this population. 
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Conclusions 
The immunological dysfunction associated with HIV creates an environment that 
is favorable to developing psoriasis. The main postulated mechanisms are T cell 
imbalance and HIV being a source of superantigens, and a costimulatory factor through 
antigenic presentation. 
Treatment of HIV-associated psoriasis can be challenging, and should be based 
on disease severity and the risks and benefits of each treatment should also be 
considered carefully. Recommended first line treatments include topical therapy, 
phototherapy, ART and secondarily oral retinoids. For refractory disease cautious 
treatment with systemic immunosupressants should be considered. Biologic agents may 
prove to be a good option in these cases. Regardless of therapy HIV patients should be 
followed up carefully for potential adverse events, with regular monitoring of CD4 
counts and HIV viral loads.  
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